Phase 2a, Randomized, Double-Blind Study to Investigate the Safety and Efficacy of Faldaprevir in Combination With Ribavirin and TD-6450 for 12 Weeks in Treatment-Naive Patients Chronically Infected With Genotype 4 Hepatitis C Virus
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2017
At a glance
- Drugs TF 6450 (Primary) ; Faldaprevir; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Trek Therapeutics
- 13 Feb 2017 Results published in a Trek Therapeutics media release.
- 13 Feb 2017 Results from this trial will be presented at the Asian Pacific Association for the Study of the Liver (APASL) conference, according to a Trek Therapeutics media release.
- 27 Jan 2017 Status changed from active, no longer recruiting to completed.